

Review of: "Advancements in the Detection and Treatment of Rare ALK Fusion Mutations in Hepatocellular Carcinoma: A Case Report and Literature Review"

Silvia Cesario¹

¹ University of Pisa

Potential competing interests: No potential competing interests to declare.

I read with attention Qui Yan's work.

Although precision medicine has shown significant success in multiple cancer types, its application in HCC remains in its infancy.

I would like to know some information about the patient in the clinical case.

Was an instrumental evaluation of the liver conducted after the bronchoscopy diagnosis? After the histological diagnosis of hepatocarcinoma, was the etiology of the disease investigated?

In certain countries, NGS is only recommended for tumors that can be treated with targeted therapy. I'm curious if your institution follows the same guidelines for all NGS testing. It would be helpful to consider the differences in NGS recommendations across various countries to clarify this aspect.

Was the NGS test conducted since no clear etiology was found for the hepatocarcinoma?

Could you please clarify why the patient did not receive the standard treatment for hepatocellular carcinoma immediately? Has the decision to initiate standard treatment been discussed with the Tumor Molecular Board? Please clarify.

"Has the patient experienced any toxicity? Please take necessary measures.

In the third paragraph of the discussion, to which pathology are you referring? Is it related to the lung cancer or other cancers?